Reason for request
Re-assessment of the Actual Benefit and Improvement in Actual Benefit in accordance with article R-163-21 of the Social Security Code.
Clinical Benefit
| Substantial |
The actual benefit of ABILIFY in the treatment of schizophrenia remains substantial. |
Clinical Added Value
| moderate |
ABILIFY, like all other antipsychotics (including typical antipsychotics), provides a moderate improvement in actual benefit (IAB III) to the management of schizophrenia. |
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
z4rMPCLreC0NzYy2
